NANOPTiX: In vivo dosimetry of ionizing radiation

CONTEXT

Cancer is a growing disease as this pathology represents 8 millions death per year in the whole world.

Radiotherapy is actually used for 60% of cancer treatments even if this technique exhibits several drawbacks concerning the lack of reliable real-time dose monitoring.  

These limits lead to significant therapeutic threshold effects, as 5% of dose variation give rise to 20% variation of the tumor control probability and 30% variation of the normal tissue complication probability.

NANOPTiX technology has been developed to overcome these obstacles by adding reliable and precise tool for ionizing radiation monitoring.

From decade ago, in vivo dosimetry has became a regulatory standard to monitor the adequacy between real dose received by patients versus prescribed dose. This obligation concerns only the beams technically measurables and highlights strong needs for this type of technologies.

DESCRIPTION

The NANOPTiX technology consists of a inert, passive and compact fiber probe.

Thanks to the particular structural assembling of materials, this technology lifts the well known locks of the fiber probes. This allows to obtain a small size fiber (< 100 µM) with high signal quality.

COMPETITIVE ADVANTAGES

• Small size (optical fiber size < 100 µM), allowing to minimize invasive character on the patient while conserving high efficiency

• NANOPTiX fibers have a high sensibility and spatial resolution by their multi-probe sensors properties

• These disposable fibers have potentially a low cost.

 
MARKETS AND APPLICATIONS

Medicine - radiotherapy :

• Brachytherapy and external beam radiotherapy
• Very localized + high dose gradient therapies (Proton therapy and Hadron therapy)
• MRI-LINAC
• MicroBeam radiotherapy 

 
DEVELOPMENT STAGE

Preliminary « physical probes »

Ready and start to be tested in clinical environment by prototyping medical probes

RESEARCH TEAM

Institute FEMTO-ST

University of Franche-Comté - CNRS

INTELLECTUAL PROPERTY

French Patent pending

TARGET PARTNERSHIP

Patent licensing

CONTACT

Thomas BLUM

Business Developer

+33 (0)6 17 06 68 07

thomas.blum@sayens.fr